Ascletis Pharma Inc
HKEX:1672
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Ascletis Pharma Inc
HKEX:1672
|
CN |
|
FRONTEO Inc
TSE:2158
|
JP |
|
E
|
East Asia Holdings Investment Ltd
KOSDAQ:900110
|
HK |
Ascletis Pharma Inc
Ascletis Pharma, Inc. operates as biotechnology firm to test the waters. The company is headquartered in Hangzhou, Zhejiang and currently employs 266 full-time employees. The company went IPO on 2018-08-01. The firm is focused on three therapeutic areas, including anti-viral, cancer and fatty liver disease. The Company’s main products include drugs against hepatitis C virus (HCV), human immunodeficiency virus (HIV) and hepatitis B virus (HBV).
Ascletis Pharma, Inc. operates as biotechnology firm to test the waters. The company is headquartered in Hangzhou, Zhejiang and currently employs 266 full-time employees. The company went IPO on 2018-08-01. The firm is focused on three therapeutic areas, including anti-viral, cancer and fatty liver disease. The Company’s main products include drugs against hepatitis C virus (HCV), human immunodeficiency virus (HIV) and hepatitis B virus (HBV).